Filana Therapeutics (FLNA) Q3 2026 earnings review
Filana clears its FDA hold, but lawsuit escrow halves cash
Filana Therapeutics won clearance to restart human drug testing while its legal settlement took nearly half its available cash. In September, US regulators lifted their nine-month hold on simufilam, the biotech's experimental seizure pill for a rare genetic disorder, and chief executive Rick Barry expects patient screening to begin by the first quarter of 2027. Unrestricted cash dropped to $47 million after the company moved $31 million into a lawsuit escrow account and burned $6 million in third-quarter operations by our math.
| Unrestricted cash | $47.0M down from $82.7M in Q2 after $31.25M escrow transfer |
|---|---|
| Q3 operating cash burn | $6.1M by our math, up from $3.8M in Q2 |
| Net loss per share | $0.22 unchanged from a year ago |
| Year-end 2026 cash outlook | Raised $2M new range: $38M to $42M |
⚖️ Verdict: 🟢 Bullish
The story got better because lifting the regulatory hold reopens the company's only clinical path. Management also raised its year-end cash outlook by $2 million, though by our math the plan still implies operating cash burn rising to about $7 million in the fourth quarter. Two cautions remain: administrative overhead still consumes nearly twice as much money as research, and the share count crept up by two million shares.
The question now is whether $47 million in unrestricted cash can fund the 40-patient epilepsy trial to a result without further share dilution. If the 13 US clinics enroll quickly and overhead comes down, existing cash can cover the 16-week study; if enrollment drags or legal bills stay high, the company will need more capital. The pace of site openings in the first quarter of 2027 will give the first read.
🐂 Bull Case
FDA Lifts Hold on Epilepsy Drug Trial
Filana Therapeutics develops simufilam, an experimental pill for seizures caused by Tuberous Sclerosis Complex (TSC), a rare genetic disorder. In December 2025, US regulators blocked the company from starting human tests and asked for more lab data and trial changes. That hold froze the drugmaker's only active clinical program after it shut down its Alzheimer's disease trials earlier in 2025.
"We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027," chief executive Rick Barry said. The Phase 2a trial will test two doses "administered in addition to standard of care therapy" in about 40 patients across 13 US clinics for 16 weeks.
Clearing the hold removes the biggest barrier facing the Texas biotech, because it can now test its drug in patients again. Still, the regulatory delay pushed the start of patient screening back by more than six months from the company's original target of the first half of 2026.
What to watch: confirmation that patient screening has begun in the first quarter of 2027. Starting on time will determine when the company can report initial 16-week seizure data from the 40-patient study.
Filana Raised Its Year-End Cash Target
Because the drug developer has no products for sale, investors track how fast it spends its bank balance. Management raised its year-end 2026 cash outlook by $2 million to a range of $38 million to $42 million, up from $36 million to $40 million three months ago. At the same time, it kept its second-half operating cash burn plan at $11 million to $15 million.
By our math, subtracting first-half operating cash use of $12.7 million from the nine-month total of $18.8 million leaves $6.1 million burned in the third quarter. The second-half plan implies about $6.9 million of operating cash burn in the fourth quarter at the middle of the range. Raising the cash target without cutting the spending plan points to roughly $1.7 million of non-operating cash inflows during the quarter.
What to watch: fourth-quarter operating cash burn against the implied $6.9 million pace. Staying near that level would give the business nearly three years of funding at current spending rates.
🐻 Bear Case
Lawsuit Escrow Cut Available Cash by 43%
Last year Filana recorded a $31.25 million charge to settle shareholder lawsuits stemming from its discontinued Alzheimer's program. Until July, the company kept that money in its main bank accounts and earned interest on the balance while waiting for a formal settlement agreement.
On July 23, the biotech transferred $31.25 million into a restricted escrow account "subject to a court approved disposition". That transfer, combined with $6.1 million of third-quarter operating cash burn by our math, cut unrestricted cash by 43% in three months, from $82.7 million in June to $47.0 million in September. Lower available cash also cut quarterly interest income by 55% from a year ago, to $0.5 million.
What to watch: final court approval of the $31.25 million settlement in the upcoming quarterly filings. Once a judge approves the deal, both the restricted cash and the matching liability will leave the balance sheet.
Overhead Still Doubles Research Spending
Filana highlighted that third-quarter general and administrative expenses — executive pay, legal bills and office overhead — fell 6% from a year ago to $7.4 million on lower stock-based pay. However, overhead jumped 21.6% from the second quarter's $6.1 million, and it still makes up 65.7% of the company's $11.3 million in total operating expenses by our math.
Research and development spending went the same way, falling 2% from a year ago to $3.9 million while rising 17.1% from the second quarter's $3.3 million as staff prepared for the epilepsy trial. Even with trial preparations underway, the biotech spends nearly two dollars on corporate overhead for every dollar it puts into lab and clinical work.
What to watch: whether research spending overtakes administrative overhead once the 13 clinical sites open in early 2027. Persistent legal and overhead costs above $7 million a quarter would drain cash meant for patient trials.
Share Count Rose by Two Million Shares
The company kept its total shares outstanding unchanged at 48.3 million for four straight reports, from November 2025 through July 2026. In this release, Filana reported 50.3 million shares outstanding as of November 5, an increase of 2.0 million shares, or 4.1% by our math, in just over three months.
Because the new shares arrived late in the third quarter or in October, weighted-average shares for the quarter barely moved at 48.5 million. Balance-sheet common stock and paid-in capital rose by $5.1 million from June to $583.7 million, which exceeds usual quarterly stock compensation and points to share sales or option exercises.
What to watch: the financing section of the third-quarter 10-Q filing. It will disclose whether management sold stock on the open market to raise that extra cash.
👓 Other Themes
Yale Cell Study Backs Epilepsy Drug
In October, researchers at Yale School of Medicine published a lab study of simufilam in the journal Cells. The researchers tested the drug in human cells lacking the TSC2 gene and found effects on "cellular stress-related signaling and mitochondrial function". The paper adds lab evidence supporting the upcoming epilepsy trial, though lab results in cells do not guarantee the pill will reduce seizures in human patients.
💲 Other KPIs
Filana lost $10.7 million, or $0.22 per share, almost unchanged from the $10.8 million loss a year ago. Compared with the second quarter of 2026, the net loss widened from $8.6 million, or $0.18 per share, because both overhead and trial preparation costs rose and interest income fell.
Short-term bills and legal accruals rose 3.8% from $39.3 million in June, by our math. Because the $31.25 million lawsuit settlement sits in restricted escrow awaiting a judge's sign-off, the liability remains on the balance sheet; stripping it out leaves $9.5 million in regular payables.
🔮 Guidance
Raised. Management lifted its year-end unrestricted cash target by $2 million at the middle of the range, to $40 million. By our math, ending the year at $40 million from September's $47.0 million implies a fourth-quarter net cash drop of $7.0 million, leaving the bank balance down 58% for the full year after the lawsuit escrow transfer.
Unchanged. The biotech still expects operations to burn $13 million in the second half at the middle of the range, marginally above the $12.7 million used in the first half. By our math, after burning $6.1 million in the third quarter, the outlook leaves $6.9 million of operating cash use for the fourth quarter as clinic activation begins.
❓ Key Questions
Where did the two million new shares come from?
Shares outstanding rose from 48.3 million in July to 50.3 million in November, and paid-in capital increased by $5.1 million in the third quarter. Did Filana sell shares through an at-the-market offering, or did insiders exercise options?
When will the 40-patient epilepsy trial read out?
Patient screening starts by the first quarter of 2027, followed by a four-week baseline and a 16-week treatment period across 13 US sites. Management has not stated how many months enrollment will take or when top-line results will arrive.
Why did overhead jump 22% from the second quarter?
General and administrative expenses climbed from $6.1 million in the second quarter to $7.4 million in the third quarter. With the securities lawsuit settlement already in escrow, what drove the $1.3 million quarterly rise in overhead?
What will the Phase 2a trial cost in 2027?
Second-half operating cash burn is running near $13 million before patients enroll. Once 13 clinics begin screening 40 patients and running 48-week extensions in 2027, how much will quarterly research spending increase?